-
1 month ago | 
seacoastonline.com | Michael Blackman
When chiropractic treatment is mentioned, too often people think of drop tables and “backs getting cracked.” The impression is one of rather rough handling and questionable health benefits. How chiropractic treatment works and its benefits has long been misunderstood, and today’s chiropractic is a far cry from earlier methodologies.
-
1 month ago | 
medcitynews.com | Frank Vinluan |Michael Blackman |Eve McDavid
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel targets to trigger weight loss. Under deal terms announced Monday, AbbVie will pay Danish company Gubra $350 million up front for rights to its drug, GUB014295. AbbVie will lead further clinical development as well as commercialization.
-
1 month ago | 
medcitynews.com | Marissa Plescia |Eve McDavid |Michael Blackman
This roundup is meant to highlight some of the most notable funding rounds of the month and is not intended to be comprehensive. Health tech companies made several major funding announcements in February. Here is a list of some of the biggest funding rounds. OpenEvidence secures $75 million in Series A fundingOpenEvidence is a company that aims to expand the world’s medical knowledge. It offers an AI copilot for doctors that helps them make medical decisions at the point of care.
-
1 month ago | 
medcitynews.com | Frank Vinluan |Stephanie Baum |Michael Blackman
A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study concluded it is unlikely to succeed. Instead, Praxis is continuing that test and a second one, adding that a decision about an FDA submission will be made after a final analysis of both studies.
-
1 month ago | 
medcitynews.com | Frank Vinluan |Michael Blackman
BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger that brings more than $450 million to support clinical testing of three drug candidates. The merger agreement announced Friday is with Helix Acquisition Corp. II, a SPAC sponsored by affiliates of Cormorant Asset Management.
-
2 months ago | 
seacoastonline.com | Michael Blackman
Winter brings plenty of outdoor fun but also a flurry of viruses that can challenge your immune system. As we spend more time indoors with more people around us, we find ourselves exposed to everything from colds to flu to COVID 19 and RSV. However, there are steps we can take to boost our immune system and help guard against illness. One key step is to get an assessment of your overall health.
-
Jan 16, 2025 | 
medcitynews.com | Sara Pastoor |Michael Blackman
The digital era is gradually taking over our institutional memory in healthcare. Every year, the next generation of physicians enters the workforce with no lived experience of a paper-based, analog medical system. I’ve been a practicing physician long enough to remember paper records, and I’ve seen the transformation from paper records to “electronic paper” to digital innovations we’d never have imagined in the 20th century.
-
Jan 15, 2025 | 
medcitynews.com | Katie Adams |Michael Blackman |Eve McDavid
Providence has proven over the last decade or so to be one of the most tech-forward health systems in the country. The Renton, Washington-based health system has conducted hundreds of tech pilots, spun out several digital health startups and funneled millions into companies creating innovative healthcare tools. Over the past eight years, Providence’s venture capital arm was a key part of the health system’s tech and innovation strategy.
-
Jan 15, 2025 | 
medcitynews.com | Frank Vinluan |Eve McDavid |Michael Blackman
Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday revised its revenue guidance for the fourth quarter to about $13.5 billion, which is about $400 million less than the company’s previous revenue projection.
-
Jan 14, 2025 | 
medcitynews.com | Arundhati Parmar |Michael Blackman
At the 43rd annual J.P. Morgan Healthcare Conference on Monday, Medtronic CEO Geoff Martha mixed in some breaking news with his usual pitch to investors. Just hours earlier, the Centers for Medicare and Medicaid had informed the company that it was opening a national coverage analysis of renal denervation and a final decision would be forthcoming sometime after the review was over on October 11, 2025.
